Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Keld Kjeldsen; Henning Bundgaard

doi:10.1111/j.1749-6632.2003.tb07285.x

Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Abstract

The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

Original language	English
Journal	Annals of the New York Academy of Sciences
Volume	986
Pages (from-to)	702-7
Number of pages	6
ISSN	0077-8923
DOIs	https://doi.org/10.1111/j.1749-6632.2003.tb07285.x
Publication status	Published - Apr 2003
Externally published	Yes

Keywords

Cardiotonic Agents/therapeutic use
Digoxin/therapeutic use
Heart/drug effects
Heart Failure/drug therapy
Humans
Myocardium/enzymology
Sodium-Potassium-Exchanging ATPase/drug effects

Access to Document

10.1111/j.1749-6632.2003.tb07285.x

Cite this

@article{57035db34fcd4f439bc67b51b69a34b3,

title = "Myocardial Na,K-ATPase and digoxin therapy in human heart failure",

abstract = "The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.",

keywords = "Cardiotonic Agents/therapeutic use, Digoxin/therapeutic use, Heart/drug effects, Heart Failure/drug therapy, Humans, Myocardium/enzymology, Sodium-Potassium-Exchanging ATPase/drug effects",

author = "Keld Kjeldsen and Henning Bundgaard",

year = "2003",

month = apr,

doi = "10.1111/j.1749-6632.2003.tb07285.x",

language = "English",

volume = "986",

pages = "702--7",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell Publishing, Inc",

}

TY - JOUR

T1 - Myocardial Na,K-ATPase and digoxin therapy in human heart failure

AU - Kjeldsen, Keld

AU - Bundgaard, Henning

PY - 2003/4

Y1 - 2003/4

N2 - The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

AB - The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

KW - Cardiotonic Agents/therapeutic use

KW - Digoxin/therapeutic use

KW - Heart/drug effects

KW - Heart Failure/drug therapy

KW - Humans

KW - Myocardium/enzymology

KW - Sodium-Potassium-Exchanging ATPase/drug effects

U2 - 10.1111/j.1749-6632.2003.tb07285.x

DO - 10.1111/j.1749-6632.2003.tb07285.x

M3 - Review

C2 - 12763921

SN - 0077-8923

VL - 986

SP - 702

EP - 707

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Abstract

Keywords

Access to Document

Fingerprint

Cite this